Cargando…

Absence of an embryonic stem cell DNA methylation signature in human cancer

BACKGROUND: Differentiated cells that arise from stem cells in early development contain DNA methylation features that provide a memory trace of their fetal cell origin (FCO). The FCO signature was developed to estimate the proportion of cells in a mixture of cell types that are of fetal origin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ze, Wiencke, John K., Koestler, Devin C., Salas, Lucas A., Christensen, Brock C., Kelsey, Karl T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642562/
https://www.ncbi.nlm.nih.gov/pubmed/31324166
http://dx.doi.org/10.1186/s12885-019-5932-6
_version_ 1783437001151741952
author Zhang, Ze
Wiencke, John K.
Koestler, Devin C.
Salas, Lucas A.
Christensen, Brock C.
Kelsey, Karl T.
author_facet Zhang, Ze
Wiencke, John K.
Koestler, Devin C.
Salas, Lucas A.
Christensen, Brock C.
Kelsey, Karl T.
author_sort Zhang, Ze
collection PubMed
description BACKGROUND: Differentiated cells that arise from stem cells in early development contain DNA methylation features that provide a memory trace of their fetal cell origin (FCO). The FCO signature was developed to estimate the proportion of cells in a mixture of cell types that are of fetal origin and are reminiscent of embryonic stem cell lineage. Here we implemented the FCO signature estimation method to compare the fraction of cells with the FCO signature in tumor tissues and their corresponding nontumor normal tissues. METHODS: We applied our FCO algorithm to discovery data sets obtained from The Cancer Genome Atlas (TCGA) and replication data sets obtained from the Gene Expression Omnibus (GEO) data repository. Wilcoxon rank sum tests, linear regression models with adjustments for potential confounders and non-parametric randomization-based tests were used to test the association of FCO proportion between tumor tissues and nontumor normal tissues. P-values of < 0.05 were considered statistically significant. RESULTS: Across 20 different tumor types we observed a consistently lower FCO signature in tumor tissues compared with nontumor normal tissues, with 18 observed to have significantly lower FCO fractions in tumor tissue (total n = 6,795 tumor, n = 922 nontumor, P < 0.05). We replicated our findings in 15 tumor types using data from independent subjects in 15 publicly available data sets (total n = 740 tumor, n = 424 nontumor, P < 0.05). CONCLUSIONS: The results suggest that cancer development itself is substantially devoid of recapitulation of normal embryologic processes. Our results emphasize the distinction between DNA methylation in normal tightly regulated stem cell driven differentiation and cancer stem cell reprogramming that involves altered methylation in the service of great cell heterogeneity and plasticity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5932-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6642562
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66425622019-07-29 Absence of an embryonic stem cell DNA methylation signature in human cancer Zhang, Ze Wiencke, John K. Koestler, Devin C. Salas, Lucas A. Christensen, Brock C. Kelsey, Karl T. BMC Cancer Research Article BACKGROUND: Differentiated cells that arise from stem cells in early development contain DNA methylation features that provide a memory trace of their fetal cell origin (FCO). The FCO signature was developed to estimate the proportion of cells in a mixture of cell types that are of fetal origin and are reminiscent of embryonic stem cell lineage. Here we implemented the FCO signature estimation method to compare the fraction of cells with the FCO signature in tumor tissues and their corresponding nontumor normal tissues. METHODS: We applied our FCO algorithm to discovery data sets obtained from The Cancer Genome Atlas (TCGA) and replication data sets obtained from the Gene Expression Omnibus (GEO) data repository. Wilcoxon rank sum tests, linear regression models with adjustments for potential confounders and non-parametric randomization-based tests were used to test the association of FCO proportion between tumor tissues and nontumor normal tissues. P-values of < 0.05 were considered statistically significant. RESULTS: Across 20 different tumor types we observed a consistently lower FCO signature in tumor tissues compared with nontumor normal tissues, with 18 observed to have significantly lower FCO fractions in tumor tissue (total n = 6,795 tumor, n = 922 nontumor, P < 0.05). We replicated our findings in 15 tumor types using data from independent subjects in 15 publicly available data sets (total n = 740 tumor, n = 424 nontumor, P < 0.05). CONCLUSIONS: The results suggest that cancer development itself is substantially devoid of recapitulation of normal embryologic processes. Our results emphasize the distinction between DNA methylation in normal tightly regulated stem cell driven differentiation and cancer stem cell reprogramming that involves altered methylation in the service of great cell heterogeneity and plasticity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5932-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-19 /pmc/articles/PMC6642562/ /pubmed/31324166 http://dx.doi.org/10.1186/s12885-019-5932-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhang, Ze
Wiencke, John K.
Koestler, Devin C.
Salas, Lucas A.
Christensen, Brock C.
Kelsey, Karl T.
Absence of an embryonic stem cell DNA methylation signature in human cancer
title Absence of an embryonic stem cell DNA methylation signature in human cancer
title_full Absence of an embryonic stem cell DNA methylation signature in human cancer
title_fullStr Absence of an embryonic stem cell DNA methylation signature in human cancer
title_full_unstemmed Absence of an embryonic stem cell DNA methylation signature in human cancer
title_short Absence of an embryonic stem cell DNA methylation signature in human cancer
title_sort absence of an embryonic stem cell dna methylation signature in human cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642562/
https://www.ncbi.nlm.nih.gov/pubmed/31324166
http://dx.doi.org/10.1186/s12885-019-5932-6
work_keys_str_mv AT zhangze absenceofanembryonicstemcelldnamethylationsignatureinhumancancer
AT wienckejohnk absenceofanembryonicstemcelldnamethylationsignatureinhumancancer
AT koestlerdevinc absenceofanembryonicstemcelldnamethylationsignatureinhumancancer
AT salaslucasa absenceofanembryonicstemcelldnamethylationsignatureinhumancancer
AT christensenbrockc absenceofanembryonicstemcelldnamethylationsignatureinhumancancer
AT kelseykarlt absenceofanembryonicstemcelldnamethylationsignatureinhumancancer